Market Clarity: Linked EHR and Claims Data
Unlock insights using one of the industry’s largest and most trusted repositories of longitudinal clinical and claims data.
Answer tough questions and illuminate new possibilities
The right real-world data (RWD) can enable your analyses to drive actions that give your organization an edge, whether it’s to optimize your portfolio, catalyze innovation, refine clinical development strategies, monitor product safety or drive commercial growth.
Traditional RWD sources only tell part of the story, though. To capture a complete view of the market and the diverse patient journeys that comprise it, you need data that link together an individual's health history with their utilization, adherence and the costs associated with their care.
That's where Optum® Market Clarity Data comes in. You can unlock insights from one of the industry's largest and most trusted repositories of de-identified clinical and multi-payer claims data, with the confidence that comes from our commitment to security and unsurpassed support. Find out where our data can shed new light on your toughest problems.
5 examples using integrated data to understand drug performance
These real-world examples show how integrated data can help you improve medication adherence, track patient journeys, evaluate total cost of care and more.
Generate evidence across the product lifecycle
Robust, linked, de-identified real-world data can help your strategy teams analyze market attractiveness and inform how you:
- Identify priority growth areas
- Vet merger and acquisition opportunities
- Assess licensing opportunities
- Reprioritize development programs
During discovery and pre-clinical development, researchers must understand the status quo. Use linked, de-identified real-world data to:
- Uncover unmet medical needs
- Understand risk profiles
- Discover biomarkers and gene targets
Granularity and trusted, high-quality data can breed confidence in your R&D pipeline. Integrated, de-identified data can help:
- Model effects of inclusion/exclusion criteria on study feasibility
- Inform endpoint selection to meet regulatory, payer and provider needs
- Quantify disease burden and therapeutic impacts on total cost of care
- Identify treatment patterns, gaps in care and barriers to adherence
Use cases for linked, de-identified data at the launch and commercialization phases are nearly endless:
- Execute comparative effectiveness studies
- Bolster payer and provider value messaging
- Uncover disparities and barriers to access
- Profile and segment both patients and physicians
- Empower medical science liaisons to engage providers with meaningful information
- Build, execute and adjudicate value-based contracts
- Track brand adoption by patient or provider segment
- Analyze adherence and switching triggers
- Pilot clinical and patient engagement programs
At the post-approval stage, linked real-world data can help you respond to regulatory commitments and perform post-market surveillance:
- Detect signals in retrospective data
- Execute Phase IV safety studies
- Model impact of new entrants and intellectual property protections
Explore these related perspectives
Four steps to an enterprise data strategy
Is Your Real-World Data Research Ready?
The unifying power of integrated data
The evolving world of clinical evidence
How is evidence generated by the life sciences used throughout health care?
Discover our other real-world data resources
Clinicogenomics data
Better understand diseases and drug development opportunities.
Electronic health record (EHR) data
Gain visibility across therapeutic areas and the continuum of care.
Claims data
Track utilization and costs through medical and pharmacy claims, lab test results, and member and provider demographics.